Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: An insight for oncologists - Abstract

Director, Advanced Prostate Cancer Program, Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/R35, Cleveland, OH 44195, USA.

 

Sipuleucel-T represents a novel immunotherapeutic compound designed to stimulate an immune response against castration-resistant prostate cancer (CRPC). Sipuleucel-T is an autologous active cellular immunotherapy product, which includes autologous dendritic cells pulsed ex vivo with PAP2024, a recombinant fusion protein made of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor. Despite the lack of prostate-specific antigen and objective response, a recent phase III randomized trial demonstrated a significant improvement in overall survival in asymptomatic and minimally symptomatic CRPC patients. This review summarizes the clinical development of Sipuleucel-T in CRPC that led to the regulatory approval of this compound in the USA.

Written by:
Garcia JA.   Are you the author?

Reference: Ther Adv Med Oncol. 2011 Mar;3(2):101-8.
doi: 10.1177/1758834010397692

PubMed Abstract
PMID: 21789160

UroToday.com Prostate Cancer Section

 

 

email news signup